Interestingly, the role of spironolactone in cardiac protocols changed its use: in the last century, it was administered in association with thiazides to avoid hypokalemia, while it is now one of the main drugs for the treatment of chronic CHF because of its antagonist activity to mineralocorticoid receptors. The gene discussed is NR3C2; the disease is congestive heart failure.